scholarly journals Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report

2017 ◽  
Vol 11 (1) ◽  
Author(s):  
Lina Frei ◽  
Ruedi Stieger ◽  
Christian Bayerl ◽  
Stefan Breitenstein ◽  
Ralph F. Staerkle
2019 ◽  
Vol 52 (3) ◽  
pp. 194-198
Author(s):  
Héctor Rodrigo Lara ◽  
Isabel Amengual Antich ◽  
Adriana Marcela Quintero Duarte ◽  
Carmen De Juan Garcia ◽  
Jose Carlos Rodríguez Pino

2012 ◽  
Vol 11 (4) ◽  
pp. 424-428 ◽  
Author(s):  
Yuichi Takano ◽  
Nobuyuki Ohike ◽  
Takuma Tajiri ◽  
Kunio Asonuma ◽  
Kenji Harada ◽  
...  

Pancreas ◽  
2011 ◽  
Vol 40 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Shunji Nagai ◽  
Tsutomu Fujii ◽  
Yasuhiro Kodera ◽  
Mitsuro Kanda ◽  
Tevfik T. Sahin ◽  
...  

2003 ◽  
Vol 10 (5) ◽  
pp. 411-413
Author(s):  
James W. Jakub ◽  
Francis D. Drake ◽  
Andrew W. Pippas ◽  
Mary Gardner ◽  
Roberto J. Fraile ◽  
...  

2005 ◽  
Vol 49 (6) ◽  
pp. 611-620 ◽  
Author(s):  
Hitoshi Hara ◽  
Koichi Suda ◽  
Toshio Oyama

2017 ◽  
Vol 10 (3) ◽  
pp. 857-862 ◽  
Author(s):  
Yen-Dun Tony  Tzeng ◽  
Shih-En Chang ◽  
Rui Mei ◽  
Manana  Javey 

Utilization of circulating tumor DNA as a novel and noninvasive test for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease. This case report describes a female with invasive ductal adenocarcinoma of the breast, where liquid biopsy was instrumental for her cancer characterization and personalized therapy selection.


Sign in / Sign up

Export Citation Format

Share Document